Research programme: norepinephrine reuptake inhibitors - Pfizer

Drug Profile

Research programme: norepinephrine reuptake inhibitors - Pfizer

Alternative Names: NRI-022; NRI-193; WAY-253203; WAY-256805; WAY-260022; WAY-315193; WAY-318068

Latest Information Update: 30 Sep 2011

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Indoles
  • Mechanism of Action Adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Anxiety disorders; Attention-deficit hyperactivity disorder; Major depressive disorder; Pain; Vasomotor symptoms

Most Recent Events

  • 30 Sep 2011 This programme is still active
  • 15 Oct 2009 Wyeth has been acquired by Pfizer
  • 01 Sep 2008 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top